A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)

Trial Profile

A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Ubenimex (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LIBERTY
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 02 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 16 Jan 2018 According to an Eiger BioPharmaceuticals media release, the company will discontinue the development of ubenimex in pulmonary arterial hypertension based on the results of this trial.
    • 16 Jan 2018 Primary endpoint (Change in pulmonary vascular resistance (PVR)) has not been met according to an Eiger BioPharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top